Brand-only drugs like Restasis, Eliquis and Lyrica can cost well over $500 for a month’s supply, and without cheaper generic alternatives, patients are often forced to either shell out their life savings or give up essential medications. FDA initiatives to expedite the drug review process and prohibit manufacturers from holding market exclusivity for too long will hopefully bring many generics to the market soon. See More
Janumet XR Latest News
Get the latest updates on this drug from the GoodRx medical team
Metformin (Glucophage) is first line therapy for diabetes which carries the benefit of helping with weight loss. It’s cheap, does not result in risky low blood sugars (hypoglycemia), has a cheap generic—oh AND it may help you live longer. In a previous blog I told you about the exciting early evidence that metformin may help prevent aging.
Well, a recent loosening of restrictions from the FDA means that 40% or 50% of patients with type 2 diabetes who have mild-moderate chronic kidney disease (CKD) will now be eligible to take metformin. See More
On August 28, 2015, the FDA issued a safety warning for a newer type of type 2 diabetes medication known as DPP-4 inhibitors or gliptins.
There have been reports that these medications can cause severe and possibly disabling joint pain.
Which medications contain gliptins (DPP-4 inhibitors)?
- Januvia (sitagliptin)
- Onglyza (saxagliptin)
- Tradjenta (linagliptin)
- Nesina (alogliptin)
- Janumet and Janumet XR (metformin and sitagliptin)
- Kombiglyze XR (saxagliptin and metformin)
- Glyxambi (empagliflozin and linagliptin)
- Jentadueto (metformin and linagliptin)
- Kazano (alogliptin and metformin)
- Oseni (alogliptin and pioglitazone)
Why was a FDA safety warning issued for gliptin medications?
The FDA issued the warning due to continued reports of severe joint pain associated with the use of gliptin medications. See More